This morning it was announced that the Italian state has asked to "stop the integration" between the medical company and the previously announced US Cyberonics - At noon the stock lost more than 8% in Piazza Affari.
Surprisingly, the funds win the majority of the assembly but the balance is turned upside down in the board - The tug of war with Bios - On May 26th new assembly to vote on the merger with Cyberonics
The insurance company sold its 4,565% stake through an accelerated book building procedure - Sorin stock slips on the stock market.
With the definitive green light for the merger with the American Igt, which will give the new group its name, the Italian Gtech becomes a global giant of games and is preparing to move its registered office to London, in the wake of Fiat: it lacks…
The Italian manufacturer of medical equipment has announced the merger with the American company active in neuromodulation - The operation values Sorin 1,2 billion dollars - The stock flies to Piazza Affari.
The joint venture between Sorin Group and MicroPort Scientific Corporation, which will be responsible for importing the Italian company's devices into China, has been officially established - Sorin said in a note, adding that the joint venture, based in Shanghai,…
The Italian company active in the production of medical equipment has completed the acquisition of the leads business of Oscor - Cost of the operation 14,5 million euros - The agreement also includes a production plant in the Dominican Republic.
Sorin Group expects consolidated revenues to increase in the 2013-2018 period and base business net earnings per share to grow more than 10% annually. These are the main estimates provided by the company in the guidelines of the Plan…
Positive closing for Sorin's third quarter of 2013 - Accounts are up on the same period of 2012, with an adjusted net result of €15,7 million - The stock accelerates and registers an increase greater than…
Last year revenues were down 1,7% to $731,1 million with earthquake impact estimated at approximately $62 million - Adjusted net income was down 28,2% to $42,1 million .
The initial investment is equal to 4,2 million euros and will be used to finance the development of technologies and clinical studies.
In the first half, growth in revenues of 2,6% to 374,1 million euros. Expected a net result of 10-12 million for the period July-September